02.16.26 -- Derisk Multimodal CGT Manufacturing With These Key CDMO Capabilities

Discover how a manufacturing platform enabled the rapid production of lentiviral vectors in eight months. Learn the strategy used to balance speed, risk mitigation, and the highest quality standards.

High-concentration formulations improve convenience but face viscosity and aggregation risks. Explore innovative strategies to optimize stability and scalability for advanced biologics development.

Achieve inducible expression in just 4-6 weeks using pre-engineered landing pads. This strategic approach significantly reduces development time and effort following donor plasmid construction.

AAV-based gene therapies show promise but face immune challenges. ELISpot assays help evaluate T cell responses, enhance clinical trial design and improving therapeutic success.

Consider our advanced sequencing protocols and bioinformatics solutions to achieve comprehensive rAAV characterization, ensuring precise analysis of purity, integrity, and identity.

See strategies for precise subvisible particle analysis, covering regulatory expectations, method validation, and controlling variability when transitioning workflows from R&D to GMP environments.

Delve into why investing in a comprehensive feasibility program for GOI testing is not just beneficial, but essential for cell and gene therapy companies.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

As cell and gene therapies continue to advance, a well-integrated analytical framework will be critical for accelerating development timelines and optimizing regulatory submissions.